Date of the CVA	30/01/2019

Section A. PERSONAL DATA

Name and Surname	SOLEDAD GALLEGO MELCON		
DNI	09695254H	Age	65
Researcher's identification number	Researcher ID		
	Scopus Author ID		
	ORCID		

A.1. Current professional situation

Institution	Instituto Catalán de la Salud			
Dpt. / Centre	Pediatric Oncology and Hematology / Hospital Vall d'HebronPediatric Oncology and Hematology			
Address	av vallcarca 68 at 1ª, 08023, barcelona			
Phone	(34) 610835365	Email	sgallego@vhebron.net	
Professional category	Head Department		Start date	2016
UNESCO spec. code	320110 - Pediatrics			
Keywords				

A.2. Academic education (Degrees, institutions, dates)

Bachelor/Master/PhD	University	Year
Master in Ethics Committees	Universidad Nacional de Educación a Distancia	2012
Doctorate in Medicine	Universitat Autònoma de Barcelona	1989
Licenciate in Medicine	FUNDACIÓN PARQUE CIENTÍFICO UNIVERSIDAD DE VALLADOLID	1977

A.3. General quality indicators of scientific production

Section B. SUMMARY OF THE CURRICULUM

Section C. MOST RELEVANT MERITS (ordered by typology)

C.1. Publications

1 **Scientific paper**. 2017. Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands.British journal of cancer.

2 **Scientific paper**. 2017. Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols.Pediatric blood & cancer.

3 **Scientific paper**. Huertas-Martínez, J.; et al. 2017. DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1

4 **Scientific paper**. Almazán-Moga, A.; et al. 2017. Hedgehog Pathway Inhibition Hampers Sphere and Holoclone Formation in Rhabdomyosarcoma

5 **Scientific paper**. Orbach, D.; et al. 2017. Nonparameningeal head and neck rhabdomyosarcoma in children and adolescents: Lessons from the consecutive International Society of Pediatric Oncology Malignant Mesenchymal Tumor studies

6 **Scientific paper**. Rogers, T.; et al. 2017. Paratesticular rhabdomyosarcoma in children and adolescents-Outcome and patterns of relapse when utilizing a nonsurgical strategy for lymph node staging: Report from the International Society of Paediatric Oncology (SIOP) Malignant Mesenchymal Tumour 89 and 95 studies

7 **Scientific paper**. Zarzosa, P.; et al. 2017. Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments
8 **Scientific paper**. Jubierre L; et al. 2016. BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways.
9 **Scientific paper**. Gallego S; Roma J. 2016. Editorial: Embryonic signaling pathways as potential targets for the treatment of rhabdomyosarcoma.
10 **Scientific paper**. Orbach D; et al. 2016. Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience.
11 **Scientific paper**. Soriano A; et al. 2016. MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes.
12 **Scientific paper**. Bautista, F.; et al. 2016. Early clinical trials in paediatric oncology in Spain: A nationwide perspective
13 **Scientific paper**. Gallego, S.; Roma, J.2016. Embryonic signaling pathways as potential targets for the treatment of rhabdomyosarcoma
14 **Scientific paper**. Boloix A; et al. 2015. [Novel micro RNA-based therapies for the treatment of neuroblastoma].
15 **Scientific paper**. Bautista, F.; et al. 2015. Landscape of early clinical trials for childhood and adolescence cancer in Spain
16 **Scientific paper**. Vella, S.; et al. 2015. MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma
17 **Scientific paper**. Boloix, A.; et al. 2015. Novel micro RNA-based therapies for the treatment of neuroblastoma
18 **Scientific paper**. Huertas-Martínez J; et al. 2014. Caveolin-1 is down-regulated in alveolar rhabdomyosarcomas and negatively regulates tumor growth.
19 **Scientific paper**. Jenney, M.; et al. 2014. Conservative approach in localised rhabdomyosarcoma of the bladder and prostate: Results from International Society of Paediatric Oncology (SIOP) studies: Malignant mesenchymal tumour (MMT) 84, 89 and 95 Pediatric Blood and Cancer. 61-2, pp.217-222.
20 **Scientific paper**. Planells-Ferrer L; et al. 2014. MYCN repression of Lifeguard/FAIM2 enhances neuroblastoma aggressiveness.
21 **Scientific paper**. Harvey, H.; et al. 2014. Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f International Journal of Cancer.
22 **Scientific paper**. Almazán-Moga, A.; et al. 2014. Optimization of rhabdomyosarcoma disseminated disease assessment by flow cytometry Cytometry Part A.
23 **Scientific paper**. Velasco, P.; et al. 2014. The role of leptin in diencephalic syndrome Pediatrics. 133-1.
24 **Scientific paper**. Soriano, A.; et al. 2013. MicroRNAs as pharmacological targets in cancer Pharmacological Research. 75, pp.3-14.
25 **Scientific paper**. Castellano, C.; et al. 2013. Surviving childhood cancer: relationship between exercise and coping on quality of life.
26 **Book chapter**. Gallego S. 2015. Sarcomas de partes blandas: Rabdomiosarcoma En: Hematología y Oncología Pediátricas (3ª ed).Ed: Madero L, Lasaleta A, Sevilla J. Ergon,. pp.633-640.
27 **Book chapter**. Gallego S. 2014. Rabdomiosarcoma y otros tumors mesenquimales malignos.Tratado de Pediatria (11ª ed).Ed: M Moro, S Malaga, L Madero. Ed. Panamericana,. pp.1752-1753.
28 **Book chapter**. Roma J; et al. 2014. miRNA-targeted therapies in the most prevalent pediatric solid tumors MicroRNA Targeted Cancer Therapy.F.H. Sarkar ed. pp.239-263.
29 **Book chapter**. Rotier B; Moreno A; Gallego S. 2013. Post-Transpant Lymphoproliferative Disorders and Cancer.Pediatric Lung Transplantation ISHLT Monograph Series. Goldfarb S, Benden C, Sweet S and Kinklin JK eds.. 7, pp.199-209.
30 **Scientific book or monograph**. Roma, J.; et al. 2014. MiRNA-targeted therapies in the most prevalent pediatric solid tumors

31 2018. Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)
32 2018. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.
33 2018. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
34 2018. Localized vaginal/uterine rhabdomyosarcoma-results of a pooled analysis from four international cooperative groups.
35 2018. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.
36 2018. Targeting of epigenetic regulators in neuroblastoma.
37 2017. Alveolar soft part sarcoma in children and adolescents: The European Paediatric Soft Tissue Sarcoma study group prospective trial (EpSSG NRSTS 2005).
38 2017. Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study.

C.2. Participation in R&D and Innovation projects

1 The oncogenic role of embryonic pathways (Notch, Hedgehog and Wnt) in rhabdomyosarcoma: expanding the knowledge to discover new therapeutic targets. Fondo de investigación Sanitaria. Josep Roma Castanyer. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 01/01/2015-31/12/2017. 116.000 €.
2 Personalized therapy against ERK5 in Neuroblastoma Miguel Segura. (AECC (Asociación Española Contra el Cáncer)). 01/01/2015-31/12/2016. 20.000 €.
3 Spanish thematic networks of cooperative research in oncology (RTICC). Aroa Soriano. (Instituto de Salud Carlos III). 01/01/2013-31/12/2016. 176.000 €.
4 MicroRNA-based therapy for high-risk neuroblastomas Josep Roma. (AECC (Asociación Española Contra el Cáncer)). 01/01/2013-31/12/2014. 18.000 €.
5 The subpopulation of tumor-initiating cells as new therapeutic target in rhabdomyosarcoma. Fondo de Investigación Sanitaria. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 01/01/2012-31/12/2014. 85.000 €.

C.3. Participation in R&D and Innovation contracts

C.4. Patents

roma josep; castells josep; gallego soledad. 18382485.3 - 1109. Compounds for use in preventing or treating cancer Spain. 22/08/2018.